Asst.Lect. Ahmed Jamal Jasim, a teaching assistant, has published a research paper in a reputable international journal indexed in the first quartile of Scopus

 titled:

"Liposome Nanocarriers Based on γ-Oryzanol: Preparation, Characterization, and In Vivo Assessment of Toxicity and Antioxidant Activity."

The study focused on lipid-based nanocarriers utilizing γ-oryzanol: their preparation, characterization, and evaluation of toxicity and antioxidant activity in vivo. These carriers were integrated into induced cellular protection of lipid particles. The abstract states that the aim of the current study is to develop and characterize lipid-based nanocarriers based on the potential of γ-oryzanol in both laboratory toxicity and in vivo antioxidant effects. The lipid particles were characterized by various physical and chemical techniques, including dynamic light scattering (DLS) for size measurements, polydispersity index (PDI), and others.

Toxicity assessments were conducted in the laboratory using blood dissolution tests and MTT assays on HSS cell lines. In vivo evaluation was performed using LD50 tests on mice. Additionally, antioxidant activity was evaluated through levels of alanine transaminase (ALT) and aspartate transaminase (AST) enzymes, catalase levels in liver tissues, and levels of malondialdehyde glutathione (GSH). Results showed that the lipid particles exhibited uniform physical and chemical properties suitable for drug delivery applications. Cellular toxicity assays and blood dissolution experiments in the laboratory indicated the potential safety of γ-oryzanol lipid particles, especially at low concentrations. Liver enzymes, such as ALT and AST, and antioxidant markers also revealed the safety of the formulation, particularly as a highly sensitive soft organ. In general, lipid-based nanocarriers formulated with γ-oryzanol were successfully developed for potential safety, supporting their application for drug delivery purposes, therapeutic interventions, liver cell treatments, and antioxidants. However, further investigations for preclinical and clinical studies are needed to explore the safety and efficacy of these lipid-based nanocarrier models and clinical settings.

Keywords: γ-Oryzanol, lipid particles, nanotechnology, drug delivery, in vivo and in vitro safety profile.